Movement Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 1, 2023.

When compared with levodopa-sparing agents, treatment levodopa alone resulted in significantly better patient-rated Parkinson’s Disease Questionnaire activities of daily living and summary index scores.

Parkinsonian syndromes, including multiple systems atrophy and progressive supranuclear palsy, have similar symptoms to Parkinson disease but are more distinct and each have corresponding therapies that are available for them.

Findings of a new novel genetic risk factor could inform future GBA1 clinical trials, improving patient stratification and the odds of designing trials that are more likely to produce meaningful and actionable answers.

A panel of former AUPN presidents detailed how advances in neurology have changed the way the clinical specialty is taught, and why collaboration among leadership remains vital to creating an effective neurology department. [WATCH TIME: 7 minutes]

Social determinants of health are conditions that people are born into and live under that affect their health, and can greatly impact clinical outcomes as well as contribute to health disparities and inequalities.

Despite the challenge of distinguishing tics from extra movements, machine learning technology could potentially help researchers with reducing time spent analyzing video recordings of patients with tic disorders.

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

Swallowing difficulties, a major concern for patients with Parkinson disease, occurred rarely in the study, and were spontaneously resolved over time.

The distinguished investigator at the National Institutes of Health provided insight on the topic of globalizing Parkinson disease genetics, and how it may lead to potential disease-modifying therapies.

The group of experts provided perspectives on the shift in how residency programs are developed and laid out, as well as efforts to increase the number of young neurologists in the field.

Previous neuroimaging studies in Parkinson disease suggest an altered interaction at a structural and functional level between cortical and subcortical areas of the brain that each contribute to gait dysfunction.

Patients treated with the probiotic saw benefits in non-motor symptoms such as sleep, fatigue, and gastrointestinal outcomes.

Falls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

After a year of treatment, patients showed significant improvements in ON time without troublesome dyskinesia, with more apparent effects observed in the high-dose group.

The neurosurgeon at Allegheny Health Network discussed the current uses of GammaTile following tumor removal, and the research needed to unlock greater potential. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Lixisenatide, commonly used to treat type 2 diabetes, has the ability to cross the blood brain barrier and has shown neuroprotective properties in preclinical models of PD.

Significant thinning of GCIPL and INL appeared earlier in individuals with Parkinson disease, being discernible several years prior to clinical presentation.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Cervical dystonia, the most common form of focal dystonia, has shown to be able to be effectively managed with a variety of botulinum toxin formulations.

Neurology News Network for the week ending August 26, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 25, 2023.

Five-year data revealed sustained and significant improvement for patients with tremor as well as an overall improvement in quality of life measures and without any progressive or delayed complications.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

A duo of experts from the pivotal, phase 3 ASPEN trial shared commentary on the impact of daxibotulinumtoxinA’s approval for adults with cervical dystonia.

Neurology News Network for the week ending August 19, 2023. [WATCH TIME: 4 minutes]

The approval was based on the phase 3 KINECT-HD study, an 128-patient cohort trial in which valbenazine met its primary end point, demonstrating a statistically significant reduction in UHDRS TMC scores vs placebo.